DNA methylation-based biomarkers in bladder cancer

Nature Reviews Urology

Volumn 10, Issue 6, 2013, Pages 327-335

  Kandimalla, Raju ^a   Van Tilborg, Angela A ^a   Zwarthoff, Ellen C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BRCA1 PROTEIN; CD99 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FRAGILE HISTIDINE TRIAD PROTEIN; GLUTATHIONE TRANSFERASE P1; K RAS PROTEIN; LAMA3 PROTEIN; NKX6.2 PROTEIN; PMF1 PROTEIN; PROTEIN BCL 2; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR NKX6.1; TRANSCRIPTION FACTOR RUNX3; TRANSCRIPTION FACTOR SOX11; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR T BET; TRANSCRIPTION FACTOR TWIST; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

BLADDER CANCER; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL DECISION MAKING; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG RESPONSE; HUMAN; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; ONCOGENE N RAS; PRIORITY JOURNAL; REVIEW; WILD TYPE;

ANIMALS; DISEASE PROGRESSION; DNA METHYLATION; HUMANS; MUSCLE NEOPLASMS; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84880274942     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.89     Document Type: Review

References (81)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011
2. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54, 303-314 (2008
3. Allard, P., Bernard, P., Fradet, Y. & Têtu, B. The early clinical course of primary Ta and T1 bladder cancer: A proposed prognostic index. Br. J. Urol. 81, 692-698 (1998
4. Kurth, K. H. et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur. J. Cancer 31A, 1840-1846 (1995
5. Habuchi, T. et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66 (Suppl. 1), 64-74 (2005
6. Sobin, L. H., Gospodarowicz, M. K. & Wittekind, C. (Eds) TNM Classification of Malignant Tumors (UICC International Union Against Cancer) (Wiley-Blackwell, New York, NY, 2009
7. Kompier, L. C. et al. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J. Pathol. 218, 104-112 (2009
8. Stenzl, A. et al. Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. Eur. Urol. 59, 1009-1018 (2011
9. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466-467 (2006
10. Rouprêt, M. et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur. Urol. 59, 584-594 (2011
11. van Rhijn, B. W. et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol. 21, 1912-1921 (2003
12. Bakkar, A. A. et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 63, 8108-8112 (2003
13. van Rhijn, B. W. et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 61, 1265-1268 (2001
14. Knowles, M. A. Bladder cancer subtypes defined by genomic alterations. Scand. J. Urol. Nephrol. Suppl. 218, 116-130 (2008
15. Esteller, M. Epigenetics in cancer. N. Engl. J. Med. 358, 1148-1159 (2008
16. Sanchez-Carbayo, M. Hypermethylation in bladder cancer: Biological pathways and translational applications. Tumour Biol. 33, 347-361 (2012
17. Laird, P. W. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3, 253-266 (2003
18. Esteller, M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8, 286-298 (2007
19. Esteller, M. Epigenetic gene silencing in cancer: The DNA hypermethylome. Hum. Mol. Genet. 16 (Spec. No. 1), R50-R59 (2007
20. Jones, P. A. & Baylin, S. B. The epigenomics of cancer. Cell 128, 683-692 (2007
21. Nishiyama, N. et al. Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. Cancer Sci. 101, 231-240 (2010
22. Wolff, E. M. et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res. 70, 8169-8178 (2010
23. Kandimalla, R. et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers. Eur. Urol. 61, 1245-1256 (2012
24. Viré, E. et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874 (2006
25. Chung, W. et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol. Biomarkers Prev. 20, 1483-1491 (2011
26. Fernandez, A. F. et al. A DNA methylation fingerprint of 1628 human samples. Genome Res. 22, 407-419 (2012
27. Reinert, T. et al. Comprehensive genome methylation analysis in bladder cancer: Identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin. Cancer Res. 17, 5582-5592 (2011
28. van Rhijn, B. W. et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J. Urol. 187, 310-314 (2012
29. Hurst, C. D., Platt, F. M., Taylor, C. F. & Knowles, M. A. Novel tumor subgroups of urothelial carcinoma of the bladder defined by integrated genomic analysis. Clin. Cancer Res. 18, 5865-5877 (2012
30. Vallot, C. et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J. Natl Cancer Inst. 103, 47-60 (2011
31. Costa, V. L. et al. Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin. Cancer Res. 16, 5842-5851 (2010
32. Lin, H. H. et al. Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. Urol. Oncol. 28, 597-602 (2010
33. Serizawa, R. R. et al. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events. Int. J. Cancer 129, 78-87 (2011
34. Marsit, C. J. et al. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 27, 112-116 (2006
35. Owen, H. C. et al. Low frequency of epigenetic events in urothelial tumors in young patients. J. Urol. 184, 459-463 (2010
36. Sobti, R. C. et al. Hypermethylation-mediated partial transcriptional silencing of DAP-kinase gene in bladder cancer. Biomarkers 15, 167-174 (2010
37. Wolff, E. M. et al. RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking. Cancer Res. 68, 6208-6214 (2008
38. Maruyama, R. et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 61, 8659-8663 (2001
39. Sathyanarayana, U. G. et al. Molecular detection of noninvasive and invasive bladder tumor tissues and exfoliated cells by aberrant promoter methylation of laminin-5 encoding genes. Cancer Res. 64, 1425-1430 (2004
40. Catto, J. W. et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J. Clin. Oncol. 23, 2903-2910 (2005
41. Marsit, C. J. et al. Epigenetic inactivation of SFRP genes and TP53 alteration act jointly as markers of invasive bladder cancer. Cancer Res. 65, 7081-7085 (2005
42. Kim, W. J. et al. RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res. 65, 9347-9354 (2005
43. Friedrich, M. G. et al. Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. Eur. J. Cancer 41, 2769-2778 (2005
44. Yates, D. R. et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin. Cancer Res. 13, 2046-2053 (2007
45. Aleman, A. et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br. J. Cancer 98, 466-473 (2008
46. Hoque, M. O. et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst. 98, 996-1004 (2006
47. Cebrian, V. et al. Discovery of myopodin methylation in bladder cancer. J. Pathol. 216, 111-119 (2008
48. Aleman, A. et al. Identification of PMF1 methylation in association with bladder cancer progression. Clin. Cancer Res. 14, 8236-8243 (2008
49. Marsit, C. J. et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS ONE 5, e12334 (2010
50. Alvarez-Mugica, M. et al. Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. J. Urol. 184, 1507-1513 (2010
51. Yan, C. et al. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer. J. Surg. Oncol. 105, 425-430 (2012
52. Kim, J. S. et al. Ras association domain family 1A: A promising prognostic marker in recurrent nonmuscle invasive bladder cancer. Clin. Genitourin. Cancer 10, 114-120 (2012
53. Agundez, M. et al. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur. Urol. 60, 131-140 (2011
54. Alvarez-Mugica, M. et al. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma. Eur. Urol. 63, 364-370 (2012
55. Zuiverloon, T. C. et al. A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine. BJU Int. 109, 941-948 (2012
56. van Rhijn, B. W., van der Poel, H. G. & van der Kwast, T. H. Urine markers for bladder cancer surveillance: A systematic review. Eur. Urol. 47, 736-748 (2005
57. Yu, J. et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin. Cancer Res. 13, 7296-7304 (2007
58. Renard, I. et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. Eur. Urol. 58, 96-104 (2010
59. Dulaimi, E., Uzzo, R. G., Greenberg, R. E., Al-Saleem, T. & Cairns, P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin. Cancer Res. 10, 1887-1893 (2004
60. Eissa, S. et al. Urinary retinoic acid receptor-β2 gene promoter methylation and hyaluronidase activity as noninvasive tests for diagnosis of bladder cancer. Clin. Biochem. 45, 402-407 (2012
61. Zhao, Y. et al. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population. PLoS ONE 7, e35175 (2012
62. Rouprêt, M. et al. A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. BJU Int. 101, 1448-1453 (2008
63. Vinci, S. et al. Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: A prospective, two-center validation study. Urol. Oncol. 29, 150-156 (2011
64. Grossman, H. B. et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J. Urol. 178, 62-67 (2007
65. Jocham, D. et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: A prospective, phase III multicenter study. J. Urol. 174, 862-866 (2005
66. Ellinger, J. et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol. 179, 346-352 (2008
67. Valenzuela, M. T. et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur. Urol. 42, 622-630 (2002
68. Shariat, S. F. et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol. Oncol. 28, 389-400 (2010
69. Baker, S. G. et al. Evaluating markers for the early detection of cancer: Overview of study designs and methods. Clin. Trials 3, 43-56 (2006
70. Bossuyt, P. M. et al. Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative. Am. J. Clin. Pathol. 119, 18-22 (2003
71. McShane, L. M. et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Urol. 2, 416-422 (2005
72. Cabello, M. J. et al. Multiplexed methylation profiles of tumor suppressor genes in bladder cancer. J. Mol. Diagn. 13, 29-40 (2011
73. Duarte-Pereira, S. et al. Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. Eur. J. Cancer 47, 1106-1114 (2011
74. Xuan, Y., Kim, S. & Lin, Z. Protein expression and gene promoter hypermethylation of CD99 in transitional cell carcinoma of urinary bladder. J. Cancer Res. Clin. Oncol. 137, 49-54 (2011
75. Lin, Y. L., Liu, X. Q., Li, W. P., Sun, G. & Zhang, C. T. Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma. Int. Urol. Nephrol. 44, 111-117 (2012
76. Chan, M. W. et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res. 8, 464-470 (2002
77. Friedrich, M. G. et al. Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients. Clin. Cancer Res. 10, 7457-7465 (2004
78. Urakami, S. et al. Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection. Clin. Cancer Res. 12, 2109-2116 (2006
79. Yates, D. R. et al. Methylational urinalysis: A prospective study of bladder cancer patients and age stratified benign controls. Oncogene 25, 1984-1988 (2006
80. Dudziec, E., Goepel, J. R. & Catto, J. W. Global epigenetic profiling in bladder cancer. Epigenomics 3, 35-45 (2011
81. Chen, P-C. et al. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine. BMC Med. Genomics 4, 45 (2011